TheraRadar
Clinical-Stage Companies / RECORDATI GROUP

RECORDATI GROUP

Pre-Approval PRO BETA
15
Total Trials
4
Phase 3
7
Phase 2
2
Recruiting
132
Score

Pipeline by Phase

Phase 3
4
Phase 2
7
Phase 1
2

Therapeutic Focus

Cushing Syndrome Pharmacokinetics Safety Hypertension Hypercortisolemia

Clinical Trials (15)

NCT01793480 Phase 3 COMPLETED

Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.

Started: 1/5/2012

NCT04125927 Phase 3 COMPLETED

Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)

Started: 9/1/2020

NCT02003742 Phase 3 TERMINATED

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Started: 9/1/2013

NCT04616586 Phase 3 TERMINATED

SILtuximab in Viral ARds (SILVAR) Study

Started: 11/13/2020

NCT03708900 Phase 2 RECRUITING

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Started: 4/28/2021

NCT05928390 Phase 2 ACTIVE NOT RECRUITING

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Started: 1/4/2024

NCT04276558 Phase 2 COMPLETED

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Started: 10/13/2020

NCT03606408 Phase 2 COMPLETED

Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Started: 10/5/2018

NCT04838860 Phase 2 TERMINATED

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Started: 3/31/2021

NCT01093807 Phase 2 COMPLETED

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Started: 3/1/2010

NCT07312643 Phase 1 COMPLETED

Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

Started: 12/1/2025

NCT03482037 Phase 1 COMPLETED

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Started: 6/7/2018

NCT07247162 Phase 4 NOT YET RECRUITING

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Started: 8/1/2026

NCT01794793 Phase 4 COMPLETED

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Started: 6/10/2013

NCT01757769 Phase 4 COMPLETED

Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia

Started: 5/1/2011

Drug Candidates

LCI699 Pasireotide ampule with syringe Osilodrostat Placebo Pasireotide Diaspartate Udonitrectag osilodrostat Methadone Pasireotide Cabergoline
Activity Status: Active
Last Trial Started: 8/1/2026
Last Trial Ended: 2/3/2026
Trials (12 months): 2
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.